688658 悦康药业
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-2.8013.4534.8788.47214.533
总资产报酬率 ROA (%)-1.7922.1243.1015.7129.752
投入资产回报率 ROIC (%)-2.2362.8014.1527.54613.012

边际利润分析
销售毛利率 (%)49.57057.80162.67164.64569.242
营业利润率 (%)-9.1394.2075.5237.88112.824
息税前利润/营业总收入 (%)-8.5484.1615.0766.97612.006
净利润/营业总收入 (%)-8.7533.2074.4687.46210.950

收益指标分析
经营活动净收益/利润总额(%)95.246142.742105.69099.087103.019
价值变动净收益/利润总额(%)-1.3271.829-0.4511.1380.641
营业外收支净额/利润总额(%)0.529-4.401-3.800-2.407-1.200

偿债能力分析
流动比率 (X)1.9842.0981.6032.0542.417
速动比率 (X)1.5491.5951.2621.6652.041
资产负债率 (%)34.15537.52439.13933.47431.426
带息债务/全部投入资本 (%)16.07218.28613.63010.9355.554
股东权益/带息债务 (%)503.071431.127612.764792.2251,651.120
股东权益/负债合计 (%)192.566166.158155.074198.333218.025
利息保障倍数 (X)-13.36131.635-20.734-9.695-18.029

营运能力分析
应收账款周转天数 (天)83.15471.67291.00781.03250.078
存货周转天数 (天)204.273167.538168.463153.642148.364